Abstract 4255: Concurrent KRAS and TP53 mutations in pancreatic cancer real-world data (RWD) highlight convergent tumor evolutionary patterns
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4255
Abstract: Pancreatic cancer is one of the most fatal of all cancers. Pancreatic adenocarcinomas have been historically difficult to treat, in part due to lack of early detection, and due to their resistance to conventional chemotherapy.… read more here.
Keywords: tp53 mutations; pancreatic cancer; kras tp53; real world ... See more keywords
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
Sign Up to like & getrecommendations! Published in 2021 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359211006950
Abstract: Lung adenocarcinomas exhibit various patterns of genomic alterations. During the development of this cancer, KRAS serves as a driver oncogene with a relatively high mutational frequency. Emerging data suggest that lung adenocarcinomas with KRAS mutations… read more here.
Keywords: immune; lung adenocarcinomas; kras tp53; kras lkb1 ... See more keywords
Mutant KRAS and TP53 with high mutation allelic frequency in ctDNA as poor outcome predictors in metastatic pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e15763
Abstract: e15763 Background: This study was to investigate the feasibility and the prognostic value of circulating tumor DNA (ctDNA) in metastatic pancreatic cancer (MPC). Methods: From 2015 to 2018 in our center, 40 MPC patients treated… read more here.
Keywords: ctdna; high maf; tissue; kras tp53 ... See more keywords
Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.25947
Abstract: KRAS and TP53 mutations, which are the most common genetic drivers of tumorigenesis, are still considered undruggable targets. Therefore, we analyzed these genetic aberrations in metastatic non-small cell lung cancer (NSCLC) for the development of… read more here.
Keywords: patients metastatic; kras tp53; non small; small cell ... See more keywords
Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.961350
Abstract: Background The main objective of this study was to analyze the effects of KRAS/TP53 mutation status and tumor sideness on the immune microenvironment of colorectal cancer using integrated scRNA-seq data. Methods A total of 78… read more here.
Keywords: cell; colorectal cancers; kras tp53; mutation ... See more keywords
Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.1022129
Abstract: Introduction: In the tumor microenvironment, interferon gamma (IFN-γ) secreted by tumor infiltrating lymphocytes can upregulate programmed cell death 1 ligand 1 (PD-L1) expression in many cancers. The present study evaluated the expression of PD-L1 in… read more here.
Keywords: cell; kras tp53; expression; colorectal cancer ... See more keywords
Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Oncology Letters"
DOI: 10.3892/ol.2019.10012
Abstract: The present study explored the association between KRAS proto-oncogene GTPase (KRAS), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA) and tumor protein p53 (TP53) mutations, and the clinical features and survival prognosis in 50 patients with non-small… read more here.
Keywords: tp53 pik3ca; pik3ca tp53; kras tp53; non small ... See more keywords